Trial Profile

Single-center, phase 2, open label, prospective cohort clinical study of Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (haic) with folfox for resectable multinodular cnlc Ib/IIa hepatocellular carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadonilimab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms Car-Hero

11 Dec 2023 Results evaluating the safety and efficacy of cadonilimab plus HAIC as a neoadjuvant management for the resectable multinodular HCC , published in the Internet Document
08 Dec 2023 New trial record
05 Dec 2023 According to a Akeso Biopharma media release, results (as of November 26, 2023) from this trial were published at the 2023 European Society of Medical Oncology Asia Congress (ESMO Asia).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com